Every 10-Q that Propanc Biopharma, Inc. (PPCB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PPCB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PPCB filings page.
Propanc Biopharma reported no revenue for the quarter ended March 31, 2026 and remains a development‑stage oncology company focused on its preclinical PRP pro‑enzyme candidate. The company posted a quarterly net loss of $6.36 million and a nine‑month net loss of $14.29 million, driven largely by stock‑based administrative expenses.
Cash increased to $443,702 at March 31, 2026 from $12,088 at June 30, 2025, supported by financing inflows including a common stock offering and issuance of Series C Preferred Stock and related warrants. Total assets were $14.33 million, mostly prepaid equity‑settled service costs, while total liabilities were $3.51 million and stockholders’ equity was $9.83 million.
Management disclosed substantial doubt about the company’s ability to continue as a going concern, citing ongoing losses, negative operating cash flow of $4.08 million over nine months, and a cumulative deficit of $140.84 million. As of May 14, 2026 there were 56,959,280 common shares outstanding, reflecting significant recent equity issuance and conversions.
Propanc Biopharma, Inc. reported results for the three and six months ended December 31, 2025, reflecting continued development-stage operations with no revenue and widening losses. The company posted a net loss of $3.1 million for the quarter and $7.9 million for the six-month period, driven mainly by $8.3 million of operating expenses, largely administration and stock-based costs.
Cash improved to $561,237 at December 31, 2025 from $12,088 at June 30, 2025, primarily due to financing activities. During August 2025, the company sold 1,000,000 common shares for $4.0 million in gross proceeds (about $3.3 million net), and in November 2025 it issued 100 shares of Series C Preferred Stock and related warrants for $1,000,099 in cash.
The accumulated deficit reached $134.5 million, and management disclosed that recurring losses, negative operating cash flow of $2.9 million over six months, and limited cash resources raise substantial doubt about the company’s ability to continue as a going concern for at least twelve months. As of February 16, 2026, there were 15,859,280 common shares outstanding, highlighting recent equity issuance and dilution as key elements of the funding strategy while the lead candidate PRP remains in preclinical development.
Propanc Biopharma (PPCB) filed its quarterly report for the three months ended September 30, 2025. The company reported no revenue and a net loss of $4,837,738, compared with a $354,310 loss a year ago. Operating expenses rose to $4,673,564 (from $290,790), driven mainly by administration expenses of $4,598,574, which included non‑cash items such as amortization of prepaid stock-based expenses.
Cash increased to $602,737 from $12,088, helped by financing inflows. The company completed an equity raise on August 18, 2025, selling 1,000,000 shares for $4,000,000 in gross proceeds and receiving approximately $3.3 million net. Total assets were $17,975,681, led by significant prepaid expenses, while total liabilities declined to $3,614,514 as convertible notes and related derivative balances decreased. The filing notes substantial doubt about the company’s ability to continue as a going concern. Common shares outstanding were 12,806,748 at September 30, 2025, and 13,364,244 as of November 13, 2025.